Featured Publications
Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology
Sirotich E, Guyatt G, Gabe C, Ye Z, Beck C, Breakey V, Cooper N, Cuker A, Charness J, de Wit K, DiRaimo J, Fein S, Grace R, Hassan Z, Jamula E, Kang M, Manski C, O'Connor C, Pai M, Paynter D, Porter S, Pruitt B, Strachan G, Webert K, Yan J, Kelton J, Bakchoul T, Arnold D. Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. Journal Of Thrombosis And Haemostasis 2021, 19: 2082-2088. PMID: 34327824, DOI: 10.1111/jth.15368.Peer-Reviewed Original ResearchConceptsImmune thrombocytopeniaSevere thrombocytopeniaGuideline panelCritical anatomical sitesLow platelet countISTH SSC SubcommitteeBleeding eventsMajor bleedsOngoing bleedPlatelet immunologyCompartment syndromeHemodynamic instabilityRespiratory compromisePhysiologic riskPlatelet countAutoimmune diseasesUrgent treatmentPatient representativesAnatomical sitesThrombocytopeniaUpcoming guidelinesPatientsBleedStandardized definitionsClinical expertsRemoving barriers and disparities in health: lessons from the COVID-19 pandemic
Sirotich E, Hausmann J. Removing barriers and disparities in health: lessons from the COVID-19 pandemic. Nature Reviews Rheumatology 2020, 17: 125-126. PMID: 33028959, PMCID: PMC7540430, DOI: 10.1038/s41584-020-00524-8.Peer-Reviewed Original ResearchPerformance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria
Gabe C, Sirotich E, Li N, Ivetic N, Nazy I, Smith J, Kelton J, Arnold D. Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria. British Journal Of Haematology 2021, 194: 439-443. PMID: 34109621, DOI: 10.1111/bjh.17566.Peer-Reviewed Original ResearchConceptsPlatelet autoantibody testingImmune thrombocytopeniaAutoantibody testingPlatelet autoantibodiesITP patientsDiagnosis of ITPCertain patient subsetsAnti-glycoprotein IIb/IIIaStrict clinical criteriaHigh pretest probabilityAntigen capture assayIIb/IIIaPatient subsetsClinical criteriaPretest probabilityTreatment responsePatientsHigher optical density valuesOptical density valuesThrombocytopeniaAutoantibodiesCapture assayDiagnosisSpecificityTesting
2024
Dermatologist and pharmacist perspectives of a collaborative co-management program
Sirotich E, Katini S, Stroedecke N, Luon S, Cohen J. Dermatologist and pharmacist perspectives of a collaborative co-management program. Archives Of Dermatological Research 2024, 316: 460. PMID: 38967646, DOI: 10.1007/s00403-024-03202-x.Peer-Reviewed Original ResearchRestrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support
Radford M, Estcourt L, Sirotich E, Pitre T, Britto J, Watson M, Brunskill S, Fergusson D, Dorée C, Arnold D. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. 2024, 2024: cd011305. PMID: 38780066, PMCID: PMC11112982, DOI: 10.1002/14651858.cd011305.pub3.Peer-Reviewed Original ResearchConceptsRed blood cell transfusion strategyHaematopoietic stem cell transplantationLiberal transfusion strategyClinically significant bleedingRestrictive transfusion strategyNon-randomised studiesTransfusion strategyIntensive chemotherapyRandomised controlled trialsRed blood cellsSignificant bleedingAll-cause mortalityLength of hospital admissionAcute leukemiaHaematological malignanciesRisk of clinically significant bleedingHaematopoietic stem cell supportProspective non-randomised studyRisk ratioControlled trialsQuality of lifeStem cell supportStem cell transplantationMalignant haematological disordersCochrane Central Register of Controlled TrialsTreatment of critical bleeding events in patients with immune thrombocytopenia: a protocol for a systematic review and meta-analysis
Sirotich E, Nazaryan H, Chowdhury S, Guyatt G, Agarwal A, Leong R, Wen A, Xu E, Liu B, Pallapothu S, Rathod P, Kwon H, Dookie J, Shafiee A, Charness J, DiRaimo J, Paynter D, Pruitt B, Strachan G, Couban R, Ye Z, Arnold D. Treatment of critical bleeding events in patients with immune thrombocytopenia: a protocol for a systematic review and meta-analysis. Systematic Reviews 2024, 13: 21. PMID: 38184622, PMCID: PMC10770981, DOI: 10.1186/s13643-023-02436-6.Peer-Reviewed Original ResearchConceptsCritical bleedingSystematic reviewEvidence-based treatment protocolsBleeding-related mortalityCochrane Central RegisterEvidence-based recommendationsFull-text screeningBleeding eventsImmune thrombocytopeniaRecommendations AssessmentCentral RegisterControlled TrialsPrimary outcomeSevere thrombocytopeniaPlatelet countEligible studiesPatient outcomesEmergency settingOvid MEDLINEObservational studyTreatment protocolHigh riskMedical emergencyElectronic databasesMethodsLiterature search
2023
Patient perspectives on telemedicine use in rheumatology during the COVID-19 pandemic: survey results from the COVID-19 Global Rheumatology Alliance
Maheswaranathan M, Miller B, Ung N, Sinha R, Harrison C, Egeli B, Degirmenci H, Sirotich E, Liew J, Grainger R, Chock E. Patient perspectives on telemedicine use in rheumatology during the COVID-19 pandemic: survey results from the COVID-19 Global Rheumatology Alliance. Clinical Rheumatology 2023, 43: 543-552. PMID: 37552351, DOI: 10.1007/s10067-023-06717-2.Peer-Reviewed Original ResearchConceptsRheumatic diseasesPerson visitsTelemedicine useMedication changesCOVID-19 pandemicCare of patientsPerspectives of patientsMethodsAn anonymous online surveyPerspectives of telemedicineDisease activityComplete responseMost patientsPatient's perspectiveTelemedicine effectivenessPatientsAnonymous online surveyFree-text responsesSimilar effectivenessDiseaseVisitsTelemedicine usersRheumatologyYounger participantsTelemedicineClinical tasks“I’d like more options!”: Interviews to explore young people and family decision-making needs for pain management in juvenile idiopathic arthritis
Toupin-April K, Gaboury I, Proulx L, Huber A, Duffy C, Morgan E, Li L, Stringer E, Connelly M, Weiss J, Gibbon M, Sachs H, Sivakumar A, Sirois A, Sirotich E, Trehan N, Abrahams N, Cohen J, Cavallo S, Hindi T, Ragusa M, Légaré F, Brinkman W, Fortin P, Décary S, Lee R, Gmuca S, Paterson G, Tugwell P, Stinson J. “I’d like more options!”: Interviews to explore young people and family decision-making needs for pain management in juvenile idiopathic arthritis. Pediatric Rheumatology 2023, 21: 74. PMID: 37491246, PMCID: PMC10369758, DOI: 10.1186/s12969-023-00849-0.Peer-Reviewed Original ResearchConceptsPain management optionsHealth care providersParents/caregiversPain managementIdiopathic arthritisPediatric health care providersBackgroundJuvenile idiopathic arthritisPain management discussionsPediatric rheumatic conditionsOttawa Decision Support FrameworkHealth-related qualityJuvenile idiopathic arthritisQualitative descriptive study designYears of ageDecision support interventionsBetter health outcomesDescriptive study designEvidence-based informationManagement optionsQuality improvement networkRheumatology nursesRheumatology consultationJoint painHCP trainingNonpharmacological approachesImpact of iron supplementation on patient outcomes for women with abnormal uterine bleeding: a protocol for a systematic review and meta-analysis
Nazaryan H, Watson M, Ellingham D, Thakar S, Wang A, Pai M, Liu Y, Rochwerg B, Gabarin N, Arnold D, Sirotich E, Zeller M. Impact of iron supplementation on patient outcomes for women with abnormal uterine bleeding: a protocol for a systematic review and meta-analysis. Systematic Reviews 2023, 12: 121. PMID: 37443063, PMCID: PMC10347734, DOI: 10.1186/s13643-023-02222-4.Peer-Reviewed Original ResearchConceptsIron deficiency anemiaQuality of lifeHeavy menstrual bleedingStandard of carePatient outcomesIron interventionsSystematic reviewUterine bleedingCombination therapyIron supplementationIron indicesRed blood cell transfusionIron deficiencyRed blood cell utilizationAbnormal uterine bleedingIntraoperative blood lossBlood cell transfusionEvidence-based clinical practiceMeta-analyzed outcomesSystematic literature searchCost of treatmentWeb of ScienceCell transfusionHospital stayAdverse eventsCharacteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
Machado P, Schäfer M, Mahil S, Liew J, Gossec L, Dand N, Pfeil A, Strangfeld A, Regierer A, Fautrel B, Alonso C, Saad C, Griffiths C, Lomater C, Miceli-Richard C, Wendling D, Rodriguez D, Wiek D, Mateus E, Sirotich E, Soriano E, Ribeiro F, Omura F, Martins F, Santos H, Dau J, Barker J, Hausmann J, Hyrich K, Gensler L, Silva L, Jacobsohn L, Carmona L, Pinheiro M, Zelaya M, de los Ángeles Severina M, Yates M, Dubreuil M, Gore-Massy M, Romeo N, Haroon N, Sufka P, Grainger R, Hasseli R, Lawson-Tovey S, Bhana S, Pham T, Olofsson T, Bautista-Molano W, Wallace Z, Yiu Z, Yazdany J, Robinson P, Smith C. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries. Annals Of The Rheumatic Diseases 2023, 82: 698-709. PMID: 36787993, PMCID: PMC10176347, DOI: 10.1136/ard-2022-223499.Peer-Reviewed Original ResearchConceptsSevere COVID-19High disease activityPandemic time periodDisease activityPsoriatic arthritisMale sexAxial spondyloarthritisCOVID-19Multivariable ordinal logistic regressionPoor COVID-19 outcomesOlder ageFuture respiratory pandemicsCOVID-19 severityCOVID-19 outcomesComorbidity burdenGlucocorticoid intakeGlucocorticoid useCancer comorbidityClinical characteristicsCOVID-19 waveRisk stratificationOrdinal logistic regressionReduced oddsSeverity ScaleRespiratory pandemic
2022
Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance
Ugarte‐Gil M, Alarcón G, Seet A, Izadi Z, Montgomery A, Duarte‐García A, Gilbert E, Valenzuela‐Almada M, Wise L, Sparks J, Hsu T, D'Silva K, Patel N, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Wallace Z, Jacobsohn L, Strangfeld A, Mateus E, Hyrich K, Gossec L, Carmona L, Lawson‐Tovey S, Kearsley‐Fleet L, Schaefer M, Machado P, Robinson P, Gianfrancesco M, Yazdany J. Association Between Race/Ethnicity and COVID‐19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID‐19 Global Rheumatology Alliance. Arthritis Care & Research 2022, 75: 53-60. PMID: 36239292, PMCID: PMC9874592, DOI: 10.1002/acr.25039.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusCOVID-19 outcomesRace/ethnicitySevere COVID-19 outcomesSystemic lupus erythematosus patientsImmunosuppressive drug useLupus erythematosus patientsCOVID-19 severityUS general populationLogistic regression modelsOrdinal logistic regression modelsGlucocorticoid doseDisease activityPandemic time periodSD ageLupus erythematosusPossible confoundersSevere outcomesMultivariable modelHigher oddsGeneral populationPatientsDrug useHealth disparitiesOutcome categoriesObstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status
Maguire S, Al-Emadi S, Alba P, Aguiar M, Al Lawati T, Alle G, Bermas B, Bhana S, Branimir A, Bulina I, Clowse M, Cogo K, Colunga I, Cook C, Cortez K, Dao K, Gianfrancesco M, Gore-Massey M, Gossec L, Grainger R, Hausman J, Hsu T, Hyrich K, Isnardi C, Kawano Y, Kilding R, Kusevich D, Lawson-Tovey S, Liew J, McCarthy E, Montgumery A, Moyano S, Nasir N, Padjen I, Papagoras C, Patel N, Pera M, Pisoni C, Pons-Estel G, Quiambao A, Quintana R, Ruderman E, Sattui S, Savio V, Sciascia S, Sencarova M, Morales R, Siddique F, Sirotich E, Sparks J, Strangfeld A, Sufka P, Tanner H, Tissera Y, Wallace Z, Werner M, Wise L, Worthing A, Zell J, Zepa J, Machado P, Yazdany J, Robinson P, Conway R. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status. Rheumatology 2022, 62: 1621-1626. PMID: 36124987, PMCID: PMC11181869, DOI: 10.1093/rheumatology/keac534.Peer-Reviewed Original ResearchConceptsObstetric outcomesPreterm birthVaccination statusPregnant womenUnvaccinated womenCOVID-19Exact testCOVID-19 vaccination statusCOVID-19 vaccine dosesCOVID-19 vaccinationCOVID-19 infectionFisher's exact testCOVID-19 diagnosisVaccine doseHospital admissionRheumatic diseasesMore dosesVaccine dosesPharmacological treatmentMusculoskeletal diseasesPregnancyDescriptive studyWomenOutcomesGreater numberProlonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, Foster G, Harrison C, Larché MJ, Levine M, Moni TT, Thabane L, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Gore-Massy M, Howard RA, Kodhek MA, Lalonde N, Tomasella LA, Wallace J, Akpabio A, Alpízar-Rodríguez D, Beesley RP, Berenbaum F, Bulina I, Chock EY, Conway R, Duarte-García A, Duff E, Gheita TA, Graef ER, Hsieh E, Kibbi L, Liew DF, Lo C, Nudel M, Singh AD, Singh JA, Singh N, Ugarte-Gil MF, Hausmann JS, Simard JF, Sparks JA. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2022, 8: e002587. PMID: 36104117, PMCID: PMC9475962, DOI: 10.1136/rmdopen-2022-002587.Peer-Reviewed Original ResearchConceptsSystemic autoimmune rheumatic diseasesCOVID-19 symptom durationSymptom durationAutoimmune rheumatic diseasesCOVID-19 onsetVaccines surveyRheumatic diseasesCOVID-19Test-confirmed COVID-19Complete symptom resolutionCOVID-19 severityCOVID-19 symptomsImmunomodulating medicationsComorbidity countSymptom resolutionBaseline characteristicsClinical characteristicsAcute symptomsVaccine dosesNovel viral variantsHigher oddsLower oddsDay 15Viral variantsLogistic regressionFactors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Yeoh S, Gianfrancesco M, Lawson-Tovey S, Hyrich K, Strangfeld A, Gossec L, Carmona L, Mateus E, Schäfer M, Richez C, Hachulla E, Holmqvist M, Scirè C, Lorenz H, Voll R, Hasseli R, Jayatilleke A, Hsu T, D’Silva K, Pimentel-Quiroz V, del Mercado M, Shinjo S, dos Reis Neto E, da Rocha L, de Oliveira e Silva Montandon A, Pons-Estel G, Ornella S, Exeni M, Velozo E, Jordan P, Sirotich E, Hausmann J, Liew J, Jacobsohn L, Gore-Massy M, Sufka P, Grainger R, Bhana S, Wallace Z, Robinson P, Yazdany J, Machado P. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. RMD Open 2022, 8: e002508. PMID: 36100295, PMCID: PMC9471207, DOI: 10.1136/rmdopen-2022-002508.Peer-Reviewed Original ResearchConceptsIdiopathic inflammatory myopathiesSevere COVID-19Prednisolone-equivalent doseHigh disease activityDisease activityInflammatory myopathiesMale sexSevere outcomesCOVID-19Multivariable ordinal logistic regressionOlder ageHigher comorbidity burdenLarge registry dataCOVID-19 diagnosisComorbidity burdenRituximab exposureClinical characteristicsRisk stratificationOrdinal logistic regressionRegistry dataHospitalisationSeverity ScaleDemographic dataLogistic regressionPatientsBaseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey
Rider L, Parks C, Wilkerson J, Schiffenbauer A, Kwok R, Farhadi P, Nazir S, Ritter R, Sirotich E, Kennedy K, Larche M, Levine M, Sattui S, Liew J, Harrison C, Moni T, Miller A, Putman M, Hausmann J, Simard J, Sparks J, Miller F, Akpabio A, Alpizar-Rodriguez D, Berenbaum F, Bulina I, Conway R, Singh A, Duff E, Durrant K, Gheita T, Hill C, Howard R, Hoyer B, Hsieh E, Kibbi L, Kilian A, Kim A, Liew D, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee C, Singh J, Singh N, Ugarte-Gil M, Wallace J, Young K, Bhana S, Costello W, Grainger R, Machado P, Robinson P, Sufka P, Wallace Z, Yazdany J, Foster G, Thabane L, Angevare S, Beesley R, Chock E, Degirmenci B, Felix C, Jin S, Mateus E, Peirce A, Sari E, Tseng R, Wang L, Zamora E. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology 2022, 61: si143-si150. PMID: 35460240, PMCID: PMC9248066, DOI: 10.1093/rheumatology/keac249.Peer-Reviewed Original ResearchConceptsSystemic rheumatic diseasesCOVID-19 vaccinationRisk factorsDisease flareRheumatic diseasesHigher oddsSARS-CoV-2 severityFlare of diseaseIdiopathic inflammatory myopathiesSystemic lupus erythematosusOxford-AstraZeneca vaccineMultivariable logistic regressionHistory of reactionPotential risk factorsPfizer-BioNTech vaccineLarge international studyImmunosuppressive medicationsInternational studiesVaccines surveyAdverse eventsInflammatory myopathiesPolymyalgia rheumaticaProspective cohortPsoriatic arthritisBaseline factorsSARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
Liew J, Gianfrancesco M, Harrison C, Izadi Z, Rush S, Lawson-Tovey S, Jacobsohn L, Ja C, Hyrich K, Gossec L, Strangfeld A, Carmona L, Schäfer M, Frãzao-Mateus E, Bulina I, Stafford F, Tufan A, Graver C, Yardımcı G, Zepa J, Al Emadi S, Cook C, Abutiban F, Dey D, Katigbak G, Kaufman L, Kowalski E, Martínez-Martínez M, Patel N, Reyes-Cordero G, Salido E, Smith E, Snow D, Sparks J, Wise L, Bhana S, Gore-Massy M, Grainger R, Hausmann J, Sirotich E, Sufka P, Wallace Z, Machado P, Robinson P, Yazdany J. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open 2022, 8: e002187. PMID: 35387864, PMCID: PMC8987210, DOI: 10.1136/rmdopen-2021-002187.Peer-Reviewed Original ResearchConceptsB-cell depleting therapyBreakthrough infectionsRheumatic diseasesSARS-CoV-2Clinical characteristicsSARS-CoV-2 breakthrough infectionsPre-existing lung diseaseSARS-CoV-2 infectionBreakthrough COVID-19Cell-depleting therapyTwo-dose seriesTime of vaccinationSecond vaccine doseHigh-risk populationMessenger RNA vaccinesCOVID-19 symptomsSingle-dose vaccineCOVID-19Vaccination seriesSystemic glucocorticoidsVaccine doseVaccine effectivenessSecond doseVaccinated individualsLung diseaseCharacteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance
Ugarte-Gil M, Alarcón G, Izadi Z, Duarte-García A, Reátegui-Sokolova C, Clarke A, Wise L, Pons-Estel G, Santos M, Bernatsky S, Ribeiro S, Al Emadi S, Sparks J, Hsu T, Patel N, Gilbert E, Valenzuela-Almada M, Jönsen A, Landolfi G, Fredi M, Goulenok T, Devaux M, Mariette X, Queyrel V, Romão V, Sequeira G, Hasseli R, Hoyer B, Voll R, Specker C, Baez R, Castro-Coello V, Ficco H, Neto E, Ferreira G, Monticielo O, Sirotich E, Liew J, Hausmann J, Sufka P, Grainger R, Bhana S, Costello W, Wallace Z, Jacobsohn L, Taylor T, Ja C, Strangfeld A, Mateus E, Hyrich K, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schäfer M, Machado P, Robinson P, Gianfrancesco M, Yazdany J. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals Of The Rheumatic Diseases 2022, 81: 970-978. PMID: 35172961, PMCID: PMC8882632, DOI: 10.1136/annrheumdis-2021-221636.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusCOVID-19 outcomesSevere outcomesDisease activityLupus erythematosusHigher SLE disease activityActive systemic lupus erythematosusMultivariable ordinal logistic regression modelsSevere COVID-19 outcomesPoor COVID-19 outcomesSLE disease activitySex-adjusted modelsMore severe outcomesCOVID-19 severityCOVID-19Logistic regression modelsOrdinal logistic regression modelsPrednisone doseMale sexGlobal RegistryWorse outcomesMultivariable modelCurrent treatmentComorbiditiesOlder age
2021
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Izadi Z, Brenner E, Mahil S, Dand N, Yiu Z, Yates M, Ungaro R, Zhang X, Agrawal M, Colombel J, Gianfrancesco M, Hyrich K, Strangfeld A, Carmona L, Mateus E, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado A, Mazeda Pereira A, Hasseli R, Pfeil A, Lorenz H, Hoyer B, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet A, Al Emadi S, Wise L, Gilbert E, Duarte-García A, Valenzuela-Almada M, Isnardi C, Quintana R, Soriano E, Hsu T, D’Silva K, Sparks J, Patel N, Xavier R, Marques C, Kakehasi A, Flipo R, Claudepierre P, Cantagrel A, Goupille P, Wallace Z, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Robinson P, Machado P, Griffiths C, Barker J, Smith C, Yazdany J, Kappelman M, Bachelez H, Capon F, Coker B, De La Cruz C, Mason K, Di Meglio P, Gelfand J, Gisondi P, Iversen L, Jullien D, Lambert J, Langan S, McAteer H, Meynell F, Moorhead L, Naldi L, Puig L, Reynolds N, Spuls P, Torres T, Tsakok T, Vincent A, Warren R, Waweru H, Ng S, Gearry R, Reinisch W, Rahier J, Lewis J, Kaplan G, Steinwurz F, Kissous-Hunt M, Modesto I, Konings M, Dahou B, Gómez G, Roberts K, Baez R, Castro Coello V, Haye Salinas M, Maldonado F, Reyes A, Alle G, Tanten R, Maldonado Ficco H, Nieto R, Gobbi C, Tissera Y, Pisoni C, Paula A, Albiero J, Schmid M, Cosatti M, Gamba M, Leandro C, Cusa M, German N, Bellomio V, Takashima L, Pera M, Cogo K, Gálvez Elkin M, Medina M, Savio V, Rojas Tessel R, Alamino R, Werner M, Ornella S, Casalla L, de la Vega M, Severina M, García M, Gonzalez Lucero L, Romeo C, Moyano S, Barbich T, Bertoli A, Baños A, Petruzzelli S, Matellan C, Conti S, Lazaro M, Rodriguez Gil G, Risueño F, Quaglia M, Scafati J, Cuchiaro N, Rebak J, Pineda S, Calvo M, Picco E, Yanzi J, Maid P, Guaglianone D, Morbiducci J, Porta S, Herscovich N, Velasco Zamora J, Kisluk B, Castaños Menescardi M, Gallo R, Martire M, Maldini C, Goizueta C, de la Vega Fernandez S, Aeschlimann C, Subils G, Rath E, Piette Y, Devinck M, Maeyaert B, Machado Ribeiro F, Euzebio Ribeiro S, Pinheiro M, Ibáñez S, Chassin Trubert A, Dong L, Cajas L, Barešić M, Anić B, Čulo M, Pavelić T, Stranski K, Karanovic B, Vencovsky J, Píchová M, Filkova M, Hamoud H, Vassilopoulos D, Guzman Melgar G, So H, Király M, Vojdanian M, Balbir Gurman A, Abutiban F, Zepa J, Bulina I, Bukauskiene L, Zazueta Montiel B, Castillo Ortiz A, Zamora Tehozol E, Vega Morales D, Cervántes Rosete D, Martín Nares E, Rodriguez Reyna T, Rull Gabayet M, Alpízar Rodríguez D, Irazoque F, Jimenez X, Geurts van Bon L, Zijlstra T, Hoekstra M, Al Adhoubi N, Salim B, Giraldo E, Salinas A, Ugarte Gil M, Nowakowski J, Conway R, Flood R, McCarthy G, Felea I, Filipescu I, Rednic S, Groseanu L, Tamas M, Mlynarikova V, Skamlova M, Zlnay M, Mičeková D, Capova L, Macejova Z, Šteňová E, Raffayova H, Belakova G, Strakova E, Senčarová M, Žlnayová S, Sabová A, Spisakova D, Oetterová M, Lukacova O, Bakosova M, Hocevar A, de la Torre Rubio N, Alegre Sancho J, Corteguera Coro M, Cobeta Garcia J, Torres Martin M, Campos J, Gomez Puerta J, Yardımcı G, Akar S, Icacan O, ÇELİK S, Vasylets V, Yeoh S, Vandevelde C, Dunt S, Leeder J, Macphie E, Salerno R, Graver C, Williams K, O'Reilly S, Devine K, Tyler J, Warner E, Pilcher J, Patel S, Nikiphorou E, Chadwick L, Jones C, Harrison B, Thornton L, O'Kane D, Fusi L, Low A, Horton S, Jatwani S, Baig S, Bajwa H, Berglund V, Dahle A, Dorman W, Hargrove J, Hilton M, Lebedoff N, Leonard S, Morgan J, Pfeifer E, Skemp A, Wilson J, Wolff A, Cepeda E, Todd D, Hare D, Calabrese C, Adams C, Khosroshahi A, Kilian A, White D, Winter M, Fields T, Siegel C, Daver N, Harvey M, Kramer N, Lamore C, Hogarty S, Yeter K, Siddique F, Ban B, Tanner T, Ruderman E, Davis W, Quinet R, Scopelitis E, Toribio K, Webb Detiege T, Zakem J, Abbass K, Kepecs G, Miranda L, Guma M, Haikal A, Mody S, Mueller D, Jayatilleke A, Zell J, Bays A, Dao K, Ezzati F, Parks D, Karp D, Quiceno G. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open 2021, 4: e2129639. PMID: 34661663, PMCID: PMC8524310, DOI: 10.1001/jamanetworkopen.2021.29639.Peer-Reviewed Original ResearchConceptsTNF inhibitor monotherapyCOVID-19-associated hospitalizationTumor necrosis factor inhibitorsNecrosis factor inhibitorsInhibitor monotherapyInflammatory bowel diseaseTNF inhibitorsCOVID-19 outcomesPooled analysisMethotrexate monotherapyImmunomodulatory treatmentMethotrexate therapyClinical characteristicsCohort studyBowel diseaseFactor inhibitorsInflammatory diseasesMAIN OUTCOMEAdverse COVID-19 outcomesCOVID-19Multivariable logistic regression modelMultilevel multivariable logistic regression modelsJAK inhibitor monotherapyKinase inhibitor monotherapyRisk of hospitalizationEarly experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpízar-Rodríguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché M, Levine M, Foster G, Thabane L, Rider LG, Hausmann JS, Simard JF, Sparks JA. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021, 7: e001814. PMID: 34493645, PMCID: PMC8424419, DOI: 10.1136/rmdopen-2021-001814.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsPatient-reported adverse eventsSystemic rheumatic diseasesCOVID-19 vaccinationRheumatic disease flareRheumatic diseasesDisease flareCOVID-19 vaccineAdverse eventsVaccine efficacyMuscle/joint painJanssen/JohnsonTime of vaccinationFever/chillsCommon rheumatic diseasePatient-reported dataOxford/AstraZenecaEarly experienceVaccines surveyAntirheumatic drugsMedication changesJoint painMost patientsPfizer-BioNTechRheumatoid arthritisCOVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance
Bermas B, Gianfrancesco M, Tanner H, Seet A, Aguiar M, Al Adhoubi N, Al Emadi S, Cunha B, Flood R, Kusevich D, McCarthy E, Patel N, Ruderman E, Sattui S, Sciascia S, Siddique F, Valenzuela-Almada M, Wise L, Worthing A, Zell J, Bhana S, Costello W, Duarte-Garcia A, Grainger R, Gossec L, Hausmann J, Hyrich K, Lawson-Tovey S, Liew J, Sirotich E, Sparks J, Sufka P, Wallace Z, Machado P, Strangfeld A, Clowse M, Yazdany J, Robinson P. COVID-19 in women with rheumatic disease who are pregnant: Data from the COVID-19 Global Rheumatology Alliance. The Journal Of Rheumatology 2021, 49: 110-114. PMID: 34470798, DOI: 10.3899/jrheum.210480.Peer-Reviewed Original ResearchConceptsRheumatic diseasesPregnant womenPregnancy outcomesObstetric detailsCOVID-19Combination of antimalarialsRheumatic disease diagnosisLopinavir/ritonavirSystemic lupus erythematosusCases of patientsCOVID-19 infectionCoronavirus disease 2019Time of infectionCOVID-19 diagnosisTime of reportAntiphospholipid syndromeInflammatory arthritidesPreterm birthLupus erythematosusMedian ageTerm birthsRheumatoid arthritisSupplemental oxygenArthritis/Medication treatment